What is the domestic and overseas selling price of Polatuzumab?

Polatuzumab (Polatuzumab) is an innovative antibody drug conjugate (ADC). Its advantages are mainly reflected in accurately targeting B cells, improving the efficacy of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL; non-Hodgkin lymphoma) and improving the quality of life of patients. It targets the CD79b antigen on the surface of B cells, allowing the cytotoxic drug MMAE to selectively enter malignant cells and exert its effects, significantly reducing damage to normal cells. This precise targeting mechanism allows velpotuzumab to achieve higher response rates and survival benefits in relapsed or refractory patients, especially for patients who have poor response to traditional chemotherapy or rituximab combination regimens.

In clinical practice, velpotuzumab is often used in combination with rituximab and chemotherapy drugs to enhance the anti-tumor effect through a synergistic mechanism. This combination not only improves the overall response rate (ORR) and complete response rate (CR), but also prolongs progression-free survival (PFS), providing an important treatment option for advanced or relapsed patients. In addition, vepotuzumab is administered by intravenous infusion, and periodic treatment allows physicians to monitor efficacy and adverse reactions while ensuring that patients are safely managed in an outpatient or inpatient setting.

Regarding price and accessibility, vepotuzumab has been launched in China and has been included in the medical insurance reimbursement items. In the domestic market, the price of 30 mg vepotuzumab per box is approximately RMB 10,000. The specific medical insurance reimbursement ratio and conditions can be implemented based on local policies and indications. Overseas, vepotuzumab was approved by the U.S. FDA in June 2019. The price per box of 30 mg is approximately US$3,900. Due to differences in innovative drug research and development costs and import channels, its price is relatively high. There is currently no publicly available generic version on the market, so patients at home and abroad mainly rely on the original drug.

Reference materials:https://www.drugs.com/polivy.html